Mylan Granted 180-Day Exclusivity On Norvasc
This article was originally published in The Pink Sheet Daily
Executive Summary
Mylan holds 180-day exclusivity on all three doses of Pfizer's Norvasc following FDA's confirmation that the generic firm was first-to-file on the 2.5 mg, 5 mg and 10 mg amlodipine doses, the company announced Oct. 4
You may also be interested in...
Generic Norvasc May Launch Sooner Than Expected Following Appellate Court Ruling
Pfizer’s hypertension treatment was predicted to go generic in September.
Generic Norvasc May Launch Sooner Than Expected Following Appellate Court Ruling
Pfizer’s hypertension treatment was predicted to go generic in September.
Pfizer’s Norvasc Does Not Infringe Synthon Patent, Court Finds
The company’s revenues stemming from its blockbuster hypertension treatment remain safe after Synthon had challenged its manufacturing process.